Member Info for dallo

Rock

Add in potentially significant Cobenfy royalties particularly if 2 of the 3 Cobenfy Adept Phase 3 trials

In Alzheimers psychosis are successfully concluded next year.

But this is Puretech and nobody seems the slightest bit interested apart from the few faithful here.

Hopefully this will change if LYT-100 is given the go ahead by the FDA to conduct Phase 3 trials and a major funding structure is put in place via a new Founded entity or partnership with another Pharma et al.

Hope springs eternal!

Rock

Gallop looks good but like every Puretech positive announcement the market shrugs and drops the SP.

It looks like only Private Equity can extract value here as management has failed abysmally.

Never experienced a share like Puretech.

Gallop LYT-200 Phase 1 results just out and look very positive.

Further information to be given at the conference tomorrow.

As expected no share price reaction in the US as yet.

It now appears that the final results of the Cobenfy Adept Study on Psychosis in Alzheimers disease will be released by the end of 2026 now that the FDA has agreed to the additional patients enrollment which analysts are suggesting stems from encouraging results shown to date.

Could be significant in the long-term for Puretech's Cobenfy royalties but short-term not great for the share price.

Bristol Myers Squibb announced today that its eagerly awaited Cobenfy trial results for psychosis in Alzheimers disease has been delayed until early next year following a number of irregularities at a small number of its study sites.

BMS said it continues to enrol patients in this pivotal trial study .

BMS shares jumped c5% on the news as Wall Street expressed relief that there was no damning negative results from the study and were encouraged that more patients were being enrolled.

The markets were expecting news on the Cobenfy Alzheimers trial by the end of this month but now pushed back a few months.

Explains the weakness in Puretech's shares of late as rumours spread that the trial was a failure .

This is not the case to date otherwise BMS would have to alert the market immediately.

Still very disappointing to see Puretech's shares trading below 120p.....10 years ago in December 2015 the shares were trading at 165p and don't mention inflation since then !!!!

Somewhat depressing.

Golfnut

I hope so as I was begining to lose the faith.

A 3% rise in Puretech is equivalent to a 30% rise in any other company given the rarity value.

ATB

Puretech had warrants to subscribe for shares in Gelesis Holdings, its weight loss founded entity which after the arrival of Ozempic et al were worthless and Gelesis closed down if memory serves me well.

I don't see warrants to subscribe for shares in Puretech but I will check financial statements, not that it is very relevant at the current SP.

Escape

Puretech sincerely apologises for the delay but normal service has now resumed and share price down despite markets rebounding.

I give up!!

Golfnut

I don't think there is any issue with LYT-100 just the US Government Shutdown is affecting the FDA like most US Departments and Agencies.

So I suspect there will be a delay on the LYT-100 FDA approval of the Phase 3 trial parameters until it is back fully operational.

Whatever happened to Tang Capital...4% is no good in terms of influence or power.

Also no news on the appointments of a full-time Chair and CEO which the market hates in a Public Company.

Escape

Nasdaq Biotechnology Index up 25% in 6 months with significant M&A activity and some smaller US and UK Biotechnology shares up multiples of their April lows.

FTSE at record high while Puretech falling to near all time lows and another short seller appearing at these low SP levels.

We still have an Interim Chair and CEO and no apparent strategy to reverse the shocking undervaluation.

Sometimes I wonder what the hell I am missing here.

Every day down for the past 6 months with a few up days after Tang Capital took a stake.

As you say quite correctly there are hundreds of overvalued rubbish companies on the market with absolutely nothing but the shorter are back again in Puretech.

With over 200 ,000 shares I am beginning to doubt this investment.

Another c 1.2 m shares short at near historic low share price.

Boy do investors hate Puretech.

803

266,000 trade not 1% of the company but just over a tenth of 1%.

Not an unusually big trade for a company with a market cap of over £320m.

Golfnut

If Puretech discovered a drug to prevent ageing , the share price would drop .

No matter what the company produces in terms of good news the market just yawns.

I don't think a financing of Celea and an announcement of the start date of the Phase 3 trial for LYT-100 will materially change the Share Price.

Only more buying by Tang Capital and /or a bid for the company will change the calculus here sadly.

ATB

More excellent news from Puretech on Gallop .

Market reaction ..share price down.

I have never seen a share like Puretech in 50 years where good news is punished by the market every time.

Nothing seems to attract the slightest interest in Puretech from the investment community while some AIM Pharma stocks multi bag on drugs going into Phase 2 not to mention Phase 3 like Celea .

Absolutely bizarre.

Correction

BMS results out on Thursday

Apologies

An important day tomorrow with BMS 3rd quarter results hopefully containing some positive news on Cobenfy revenues.

The Puretech share price and trading volumes are utterly moribund at the moment almost befitting an illiquid AIM stock .

It is the same on Nasdaq with barely a few trades every day.

BMS should bid for it now saving c $400m minimum in Cobenfy royalties, c$300m in cash, 100% of Celea and Gallop plus c35% of the Seaport plus the R&D facilities in Boston as well as significant deferred tax losses..

With no permanent Chair or CEO Puretech is ripe for a takeover.

But we have been saying this for years now and nothing ever happens.

However I feel something is about to blow and very soon imho.

Hopefully Tang Capital or Nordic Capital might stir the pot .

ATB

Jamgoo

I would love to think so but with the Nasdaq Purerech share price down 7% at the moment to new all-time low I am not optimistic.

Surely it is the perfect time for some acquirer to make a move.

According to Sales Tools AI , Seaport therapeutics has a valuation of $1.2billion following it's latest $225m funding round in October 2024 as detailed in an unspecified Report following the financing.

This adds to the bizarre undervaluation of Puretech's shares particularly as Seaport has made significant progress since October 2024.

So theoretically Puretech's market cap is equivalent to the value of its shareholding in Seaport alone.

What is it that the market doesn't understand?

The 3rd quarter results for BMS will be published on Thursday 30th October.

We will get an update on Cobenfy revenues then.

Trawl

It is increasingly hard to believe the dreadful Puretech share price in this bull market particularly as Biotech has joined the party .

No movement in Puretech's SP over past six months while Nasdaq Biotechnology Index up over 35% .

Puretech has huge cash reserves, major royalties coming from Cobenfy revenues, Seaport moving strongly ahead with c $350m funding, Celea about to embark on a LYT-100 Phase 3 trial with potentially a blockbuster drug in IPF and Gallop another great opportunity.

Tang Capital and Nordic Capital both saw a glaring anomaly in the SP but the general investment markets are still totally disinterested.

Awaiting BMS 3rd quarter results on Cobenfy and other near term catalysts to get this static SP moving.

Patience as always .

ATB